Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Supplier dossier · §4

HJ — on-the-record assessments

Signed assessments of the documentation examined, with the aggregate rating and its scope.

Document identifier
CEI-SD-11/4
Series
Supplier dossier
Version
2.2
Published
03 Jun 2024
Last reviewed
03 Oct 2024
Next review
03 Oct 2025
Identifier
10.71829/cei.supp.11
Certainty
High
Cycle
2024 Q2
Assessment score
83.0 / 100
Conformance
A

The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.

§4On-the-record assessments

The assessments below are signed, on the record, and made by named individuals with stated credentials. Each concerns the documentation the assessor examined. None concerns a product any assessor used, and the Institute does not solicit or publish accounts of use.

§4.1Aggregate

Modal certainty across assessments
High
Assessments contributing
678
Assessments published in full
26
Scope of the rating
Documentation completeness and interpretability. Not product quality.
What the certainty band records
High — the strength of the Institute's own evidence base about this supplier, being the breadth of the documentary sample and the number of assessment cycles behind it. It is not a quality verdict and nothing on this site presents it as one.
Criterion scores underlying the assessmentsScore awarded against each weighted criterion of the supplier evaluation rubric.Criterion (weight)Score, 0 to 5Certificate-of-analysis completeness25 %4 / 5Independent third-party testing record25 %4 / 5Identity confirmation practice15 %4 / 5Documentation transparency and consistency15 %5 / 5Storage, packaging and cold-chain evidence10 %4 / 5Responsiveness to documented enquiry10 %4 / 5
Figure 3. The six criterion scores. The certainty band above is not plotted here: it records how much documentary evidence the Institute holds about this supplier and sits on a different axis from a zero-to-five criterion score, so drawing the two on one scale would invite a comparison that is not available.

§4.2Published assessments

Dr Cesar Ferreira, MDHigh certainty11 Jun 2026

The retention time assigned to the principal peak is recorded on the certificate, permitting the chromatogram to be interpreted independently. The gradient and column chemistry are stated, permitting the determination to be reproduced. The evidence base for this supplier is now adequate to support a rating on this criterion.

Dr Diego Moreau, PhD (Medicinal Chemistry)High certainty18 Apr 2026

Consistency across lots was assessed over 3 determinations. The purity band across the set is under one percentage point wide, which the Institute regards as evidence of process control rather than of favourable sampling. Documentation was complete at first issue.

Dr Elodie Wojcik, MSc (Analytical Science)High certainty13 Feb 2026

Delivery was completed on day 9 against a quoted 9 days from stock held in the Netherlands. Customs documentation was correct at first presentation. Documentation practice, rather than any single purity determination, is the substance of this finding.

Dr Rohan Asante, MD, MPHHigh certainty30 Jun 2026

Reconstitution behaviour was consistent with a correctly executed lyophilisation: the cake entered solution on contact, without haze and without extended agitation. Identity was confirmed by two orthogonal methods.

Dr Hamza Guerrero, PhD (Biochemistry)High certainty16 May 2026

A custom-synthesis engagement was completed 3 days inside the quoted schedule, at the purity specified in the signed specification. Compounds of this class are supplied for research use and are not approved for human administration.

Dr Priya Tamm, MRPharmSHigh certainty21 Mar 2026

Batch traceability is complete: the identifier on the primary container corresponds to that on the certificate and to that on the commercial documentation. No adverse finding arises from the transactions described.

Dr Andres Adeyemi, PhD (Analytical Chemistry)High certainty03 Apr 2026

Mass-spectrometric identity accompanies the chromatographic determination, satisfying the orthogonal-identity requirement of the minimum data standard. The gradient and column chemistry are stated, permitting the determination to be reproduced.

Dr Rafael Baptista, PhD (Pharmaceutical Sciences)High certainty24 Jun 2025

Cold-chain integrity was maintained through transit; the phase-change pack remained solid to arrival on day 6.

Dr Kenji Danquah, MPharmHigh certainty24 Apr 2026

Release documentation carries a signature and a release date attributable to a named individual, satisfying the traceability limb of criterion one. A signature and release date appear on the certificate.

Dr Sena Batista, PharmDHigh certainty27 Jun 2026

Fill uniformity was assessed by weighing 11 units from a single consignment against declared fill. All units fell within two per cent of the declared mass. Identity was confirmed by two orthogonal methods.

Dr Sigrid Novak, MDHigh certainty04 Apr 2025

The tryptophan-containing line shipped in an amber vial without the point having to be raised. The submission is recorded in full in the evidence log.

Dr Aksel Tamm, PhD (Medicinal Chemistry)High certainty11 Nov 2025

The order acknowledgement stated the dispatching warehouse, which allows the transit history of the lot to be reconstructed. Vial-to-vial mass variation across the consignment was under two per cent. Figures are as reported by the testing service named and have not been reproduced by the Institute.

Dr Leila Ndiaye, MSc (Analytical Science)High certainty01 Mar 2026

Documentation was complete at first issue. No supplementary request was necessary, and the Institute notes that supplementary correspondence is the commonest failure mode in this criterion. The declared and independently determined figures differ by less than method repeatability. Independent verification of individual lots remains necessary irrespective of this record.

Dr Rina Laurent, MD, MPHHigh certainty06 May 2025

A repeat determination on the same catalogue line at 15 months returned 98.3%, against 98.3% originally. No evidence of process drift is present in this sample. This is a single assessor’s record and carries the weight the rubric assigns to one.

Dr Karim Pires, PhD (Biochemistry)High certainty22 Jul 2026

Material from lot HJ-24-505 was submitted to Janoshik; the determination returned 97.7% against a declared 97.8%, a difference within the stated repeatability of the method. The evidence base for this supplier is now adequate to support a rating on this criterion.

Dr Erez Ndiaye, MRPharmSHigh certainty21 Dec 2025

Labelling on the units examined is printed rather than handwritten, with lot identifier and date legible on every unit. Identity was confirmed by two orthogonal methods.

Dr Bastian Agyeman, PhD (Analytical Chemistry)High certainty28 May 2026

The storage condition against which the stability statement was written is stated on the certificate, which permits the statement to be evaluated rather than merely noted. The consignment contained no unsecured items. Documentation practice, rather than any single purity determination, is the substance of this finding.

Dr Gustav Moreau, PhD (Pharmaceutical Sciences)High certainty19 Aug 2025

Across 20 months and 4 orders no substitution, reformulation or post-payment unavailability was encountered by this assessor. Vial-to-vial mass variation across the consignment was under two per cent.

Dr Jarno Zamora, MPharmHigh certainty05 Feb 2026

Material obtained directly from the manufacturer returned 98.2%; material of nominally identical description obtained through an intermediary returned 98.2%. The comparison is offered without further comment. The gradient and column chemistry are stated, permitting the determination to be reproduced.

Dr Rohan Bhattacharya, PharmDHigh certainty05 Mar 2026

Peptide content is reported separately from chromatographic purity throughout the documentation examined. The distinction is maintained consistently across the 4 certificates held. Documentation was complete at first issue.

Dr Freya Guerrero, MDHigh certainty15 Aug 2025

Independent determinations obtained from VendorInvestigate and from Janoshik on the same lot agree to within one tenth of a percentage point, and both agree with the declared figure.

Dr Samir Delgado, PhD (Medicinal Chemistry)High certainty10 Jul 2025

The certificate carried a signature and a release date, which is the minimum on which a document of this kind can be relied. Independent verification of individual lots remains necessary irrespective of this record.

Dr Kian Broberg, MSc (Analytical Science)High certainty01 Apr 2026

Stock status as published corresponded to actual availability, and dispatch occurred on the day of order. The consignment contained no unsecured items.

Dr Amara Yilmaz, MD, MPHHigh certainty27 Feb 2025

Packing was assessed as adequate to the transit undertaken: the caps crimped evenly, none of them proud of the shoulder.

Dr Matias Verhoeven, PhD (Biochemistry)High certainty04 Jun 2026

Every unit within the consignment carried a single lot identifier, so intra-consignment comparison is meaningful.

Dr Sten Vestergaard, MRPharmSHigh certainty15 Mar 2025

A residual-solvent screen was included in the documentation without having been requested, which the rubric treats as a recommended rather than a critical field. The supplementary certificate was retrieved without demur. The assessor declares no interest in the supplier beyond the transactions described.

§4.3The supplier’s own account

Each assessment above concerns a document the assessor examined. None of them concerns what HJ says about itself, which is published at its own address and is worth reading beside them rather than instead of them.

Read HJ’s own account at hubeijianxiang.net →

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.